Metformin Worwag (Metformin Hydrochloride)

Metformin Worwag is a biguanide indicated for disorders of glucose metabolism, primarily type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels.

• Metformin Hydrochloride acts primarily by inhibiting mitochondrial respiratory-chain complex I, which decreases hepatic gluconeogenesis. It also enhances peripheral glucose uptake by increasing insulin‑mediated activation of AMP‑activated protein kinase (AMPK), leading to improved insulin sensitivity and reduced intestinal glucose absorption.

Metformin Worwag may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.
• Diarrhea: loose stools occurring especially during dose titration.
• Metallic taste: transient alteration in taste perception.
• Loss of appetite: reduced desire to eat.
• Flatulence: increased intestinal gas.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal accumulation of lactate.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: marked elevation of liver enzymes.
• Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption.
• Hypoglycemia: when combined with insulin or insulin secretagogues.

When prescribing Metformin Worwag, clinicians should consider several precautionary measures to minimize risk.

• Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
• Hepatic function monitoring: avoid use in patients with significant liver disease.
• Lactic acidosis risk: contraindicated in conditions predisposing to hypoxia or reduced perfusion.
• Concomitant drug review: assess for agents that may impair renal clearance or increase metformin levels.
• Elderly dosing considerations: start with lower dose and titrate cautiously.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Worwag can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase risk of lactic acidosis; discontinue metformin before and after imaging as advised.
• Cimetidine: can reduce renal clearance of metformin, raising plasma concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms; monitor blood glucose.
• Diuretics (loop or thiazide): can affect renal function and electrolyte balance; adjust dose as needed.
• Corticosteroids: may increase blood glucose levels, requiring tighter glycemic monitoring.